Organization · Venture Capital
Brandon Capital
Brandon Capital is a leading life science venture capital firm based in Australasia, focusing on transforming medical research breakthroughs into therapies. It has a strong global presence with partnerships in the US and UK.
Overview
What Brandon Capital does
What Brandon Capital is
Brandon Capital is a leading life science venture capital firm based in Australasia, focusing on transforming medical research breakthroughs into therapies. It has a strong global presence with partnerships in the US and UK.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Structured capabilities
- Funder
- Last reviewed
- March 17, 2026
Official channels
Find Brandon Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
Brandon Capital as a funder
Investment thesis
Brandon Capital focuses on transforming medical research breakthroughs into therapies that improve patient outcomes, exclusively investing in life sciences.
Focus narrative
Brandon Capital invests in life science companies, particularly in biotechnology and pharmaceuticals. The firm supports companies at various stages, from proof-of-concept to commercialization, with a focus on oncology, neuroscience, cardiovascular, and digital health sectors. Their investment strategy is bolstered by collaborations with medical research institutes and hospitals to source and create investment opportunities.
Value beyond capital
Brandon Capital adds value to its portfolio companies through its unique Brandon BioCatalyst initiative, which collaborates with over 50 medical research institutions to support the development and commercialization of early-stage biomedical discoveries. This network provides proprietary deal flow and access to critical resources for portfolio companies.
Terms and economics
- Typical check
- $500,000–$10,000,000
- Sweet spot
- $3,000,000
Focus and fit
- Stages
- Seed · Seed+ · Series A · Series B · Growth Equity
- Regions
- Global · Uk · United States
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 30
- Investments in the last 12 months
- 5
- Last recorded investment
- October 22, 2025
- Recorded notable exits
- EBR Systems, Pathios, and Occurx
Portfolio context
Brandon Capital has a diverse portfolio of over 30 active companies, including notable firms such as Advancell, a clinical-stage radiopharmaceutical company; Aravax, focused on immunotherapies for food allergies; and Myricx Bio, innovating in antibody-drug conjugates for cancer treatment. Other portfolio highlights include PolyActiva, developing a glaucoma implant, and Vaxxas, specializing in vaccine delivery.
Common questions
What to know about Brandon Capital
Upseed classifies Brandon Capital under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 17, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.